Amphastar Pharma (AMPH) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018
March 12, 2019 4:05 PM EDTReports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018
RANCHO CUCAMONGA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months and full year ended December 31, 2018.
Fourth Quarter Highlights
Net revenues of $89.7 million for the fourth quarter, up 48% from the quarter ended December 31, 2017GAAP net income attributable to Amphastar of $1.9 million, or $0.04 per diluted share, for the fourth quarterAdjusted non-GAAP net income attributable to Amphastar of $6.2 million, or... More